老年结直肠癌合并骨骼肌质量降低患者生存预测研究

王翠翠, 姚俊英, 李倩, 祝力, 范旻

肿瘤代谢与营养电子杂志 ›› 2026, Vol. 13 ›› Issue (1) : 134-141.

PDF(4076 KB)
PDF(4076 KB)
肿瘤代谢与营养电子杂志 ›› 2026, Vol. 13 ›› Issue (1) : 134-141. DOI: 10.16689/j.cnki.cn11-9349/r.2026.01.018
论著

老年结直肠癌合并骨骼肌质量降低患者生存预测研究

  • 1王翠翠, 1姚俊英, 1李倩, 2祝力, 1范旻
作者信息 +

Survival prediction in elderly patients with colorectal cancer complicated by reduced skeletal muscle mass

  • 1Wang Cuicui, 1Yao Junying, 1Li Qian, 2Zhu Li, 1Fan Min
Author information +
文章历史 +

摘要

目的 构建并验证基于可解释性极端梯度提升(XGBoost)算法的老年结直肠癌合并骨骼肌质量降低患者生存预测模型。方法 回顾性纳入2018年7月至2023年12月新疆维吾尔自治区人民医院528例确诊为骨骼肌质量降低的老年结直肠癌患者,收集一般资料、实验室及影像学数据。采用最小绝对收缩和选择算子(Lasso)回归和XGBoost算法筛选特征变量,结合SHAP值分析特征重要性,并基于多因素Cox比例风险回归模型构建列线图模型。通过一致性指数(C-index)及时间依赖受试者操作特征(ROC)曲线及其曲线下面积(AUC)分析评估模型性能。结果 最终纳入的关键变量包括年龄、预后营养指数(PNI)、营养控制评分(CONUT)、癌胚抗原(CEA)、糖类抗原242(CA242)和C反应蛋白(CRP)为危险因素,骨骼肌指数(SMI)为保护因素。XGBoost模型在训练集和验证集中均表现出良好的区分度和稳健性,校准曲线拟合良好,决策曲线分析显示具有较高临床应用价值。结论 基于可解释性XGBoost算法构建的生存预测模型能够有效识别影响老年结直肠癌合并骨骼肌质量降低患者总生存期(OS)和癌症特异性生存期(CSS)的关键预后因子,为临床风险分层与个体化干预提供参考。

Abstract

Objective To develop and validate a survival prediction model for elderly patients with colorectal cancer complicated by reduced skeletal muscle mass based on an interpretable Extreme Gradient Boosting (XGBoost) algorithm. Methods A total of 528 elderly patients diagnosed with colorectal cancer complicated by reduced skeletal muscle mass at the People's Hospital of Xinjiang Uygur Autonomous Region from July 2018 to December 2023 were retrospectively enrolled. General clinical characteristics, laboratory test results, and imaging data were collected. Least absolute shrinkage and selection operator (Lasso) regression and the XGBoost algorithm were used for feature selection. Feature importance was further interpreted using SHapley Additive exPlanations (SHAP) values, and a nomogram prediction model was constructed based on a multivariable Cox proportional hazards regression model. Model performance was evaluated using the concordance index (C-index) and time-dependent receiver operating characteristic (ROC) curves along with the corresponding area under the curve (AUC). Results The final model incorporated age, prognostic nutritional index (PNI), controlling nutritional status (CONUT) score, carcinoembryonic antigen (CEA), carbohydrate antigen 242 (CA242), and C-reactive protein (CRP) as risk factors, while skeletal muscle index (SMI) was identified as a protective factor. The XGBoost model demonstrated good discrimination and robustness in both the training and validation cohorts. Calibration curves showed good agreement, and decision curve analysis indicated favorable clinical utility. Conclusion The interpretable XGBoost-based survival prediction model can effectively identify key prognostic factors associated with overall survival (OS) and cancer-specific survival (CSS) in elderly patients with colorectal cancer complicated by reduced skeletal muscle mass, providing a reference for clinical risk stratification and individualized intervention.

关键词

老年结直肠癌 / 骨骼肌质量降低 / 极端梯度提升算法 / 列线图 / 生存预测模型 / 营养控制评分 / 预后分析

Key words

Elderly colorectal cancer / Reduced skeletal muscle mass / Extreme gradient boosting algorithm / Nomogram / Survival prediction model / Controlling nutritional status score / Prognostic analysis

引用本文

导出引用
王翠翠, 姚俊英, 李倩, 祝力, 范旻. 老年结直肠癌合并骨骼肌质量降低患者生存预测研究[J]. 肿瘤代谢与营养电子杂志. 2026, 13(1): 134-141 https://doi.org/10.16689/j.cnki.cn11-9349/r.2026.01.018
Wang Cuicui, Yao Junying, Li Qian, Zhu Li, Fan Min. Survival prediction in elderly patients with colorectal cancer complicated by reduced skeletal muscle mass[J]. Electronic Journal of Metabolism and Nutrition of Cancer. 2026, 13(1): 134-141 https://doi.org/10.16689/j.cnki.cn11-9349/r.2026.01.018

参考文献

[1] FERLAY J, ERVIK M, LAM F, et al. Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2024,74(3):229-263.
[2] XIE B, WANG J, WANG C, et al. Determining the effects of social-environmental factors on the incidence and mortality of lung cancer in China based on remote sensing and GIS technology during 2007-2016[J]. BMC Public Health,2025,25(1):1673.
[3] MIYAMOTO Y, BABA Y, SAKAMOTO Y, et al. Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer[J]. Ann Surg Oncol,2015,22(8):2663-2668.
[4] HE J, LUO W, HUANG Y, et al. Sarcopenia as a prognostic indicator in colorectal cancer: An updated meta-analysis[J]. Front Oncol,2023,13:1247341.
[5] LIN W L, LIU Y, ZHANG J, et al. Sarcopenia and survival in colorectal cancer: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol,2024,39(7):1598-1608.
[6] CHO H J, KANG J. Sarcopenia diagnosis in patients with colorectal cancer: a review of computed tomography-based assessments and emerging ways to enhance practicality[J]. Ann Surg Treat Res,2024,106(6):305-312.
[7] CHO H J, LEE H S, KANG J. Varying clinical relevance of sarcopenia and myosteatosis according to age among patients with postoperative colorectal cancer[J]. J Nutr Health Aging,2024,28(7):100243.
[8] VERGARA-FERNANDEZ O, TREJO-AVILA M, SALGADO-NESME N. Sarcopenia in patients with colorectal cancer: a comprehensive review[J]. World J Clin Cases,2020,8(7):1188-1202.
[9] OJIMA Y, HARANO M, SUMITANI D, et al. Impact of preoperative skeletal muscle mass and quality on the survival of elderly patients after curative resection of colorectal cancer[J]. J Anus Rectum Colon,2019,3(4):143-151.
[10] RIAD M, HASSAN M, NAIR K, et al. Impact of neoadjuvant chemotherapy on skeletal muscle mass in colorectal cancer patients undergoing curative surgical resection: a single-centre retrospective observational study[J]. Cureus, 2025, 17(8): e89389.
[11] CHANG Y Y, CHENG B. Prognostic impact of myosteatosis in patients with colorectal cancer undergoing curative surgery: an updated systematic review and meta-analysis[J]. Front Oncol,2024,14:1388001.
[12] XIAO J, CAAN B J, CESPEDES FELICIANO E M, et al. Association of low muscle mass and low muscle radiodensity with morbidity and mortality for colon cancer surgery[J]. JAMA Surg,2020,155(10):942-949.
[13] LIM J Y, KIM Y M, LEE H S, et al. Skeletal muscle gauge prediction by a machine learning model in patients with colorectal cancer[J]. Nutrition,2023,115:112146.
[14] SORIA-UTRILLA V, SáNCHEZ-TORRALVO F J, PALMAS-CANDIA F X, et al. AI-assisted body composition assessment using CT imaging in colorectal cancer patients: predictive capacity for sarcopenia and malnutrition diagnosis[J]. Nutrients,2024,16(12):1864.
[15] SEOK M, KIM W, KIM J. Machine learning for sarcopenia prediction in the elderly using socioeconomic, infrastructure, and quality-of-life data[J]. Healthcare (Basel),2023,11(21):2854.
[16] PAVÓN-PULIDO N, DOMINGUEZ L, BLASCO-GARCÍA J D, et al. Identification of predictors of sarcopenia in older adults using machine learning: English longitudinal study of ageing[J]. J Clin Med,2024,13(22):6841.
[17] PRADO C M, LIEFFERS J R, MCCARGAR L J, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study[J]. Lancet Oncol,2008,9(7):629-635.
[18] ISEKI Y, SHIBUTANI M, MAEDA K, et al. Impact of the preoperative controlling nutritional status (CONUT) score on the survival after curative surgery for colorectal cancer[J]. PLoS One, 2015, 10(7): e0132488.
[19] TOKUNAGA R, SAKAMOTO Y, NAKAGAWA S, et al. Conut: a novel independent predictive score for colorectal cancer patients undergoing potentially curative resection[J]. Int J Colorectal Dis,2017,32(1):99-106.
[20] HAYAMA T, OZAWA T, OKADA Y, et al. The pretreatment controlling nutritional status (CONUT) score is an independent prognostic factor in patients undergoing resection for colorectal cancer[J]. Sci Rep,2020,10(1):13239.
[21] SHANG J, WEI J. Prognostic significance of the pretreatment controlling nutritional status score in colorectal cancer patients: An updated meta-analysis with 24 cohort studies[J]. Front Nutr,2025,12:1560355.
[22] CARPELAN-HOLMSTRM M, HAGLUND C, LUNDIN J, et al. Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer[J]. Eur J Cancer,1996,32A(7):1156-1161.
[23] VON KLEIST S, HESSE Y, KANANEEH H. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon[J]. Anticancer Res,1996,16(4B):2325-2331.
[24] CENDRA A S, PEKAREK L, OSPINO L R, et al. Predictive and prognostic biomarkers of recurrence in locoregional colorectal cancer[J]. J Cancer,2025,16(10):3024-3039.
[25] RAMPHAL W, BOEDING J R E, VAN IWAARDEN M, et al. Serum carcinoembryonic antigen to predict recurrence in the follow-up of patients with colorectal cancer[J]. Int J Biol Markers,2019,34(1):60-68.
[26] HWANG S H, SHIN S H, KIM Y J, et al. Risk factors for recurrence in stage I colorectal cancer after curative resection: a systematic review and meta-analysis[J]. Ann Surg Treat Res,2025,108(1):39-48.
[27] YANG X Q, CHEN C, PENG C W, et al. Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases[J]. Med Oncol,2012,29(2):1030-1036.
[28] KIM H G, YANG S Y, HAN Y D, et al. Association of perioperative serum carcinoembryonic antigen level and recurrence in low-risk stage IIA colon cancer[J]. PLoS One, 2021, 16(6): e0252566.
[29] KIM C W, YOON Y S, PARK I J, et al. Elevation of preoperative s-CEA concentration in stage IIA colorectal cancer can also be a high risk factor for stage II patients[J]. Ann Surg Oncol,2013,20(9):2914-2920.
[30] HUANG C S, CHEN C Y, HUANG L K, et al. Prognostic value of postoperative serum carcinoembryonic antigen levels in colorectal cancer patients who smoke[J]. PLoS One, 2020, 15(6): e0233687.
[31] KIM E S, KIM S Y, MOON A. C-reactive protein signaling pathways in tumor progression[J]. Biomol Ther (Seoul),2023,31(5):473-483.
[32] ZHOU Q P, LI X J. C-reactive protein to albumin ratio in colorectal cancer: a meta-analysis of prognostic value[J]. Dose Response,2019,17(4):1559325819889814.
[33] FURUKAWA S, HIRAKI M, KIMURA N, et al. The potential of the C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in colorectal cancer[J]. Cancer Diagn Progn,2025,5(3):370-377.
[34] SUN J, LI Z, ZHU X. Prognostic role of prognostic nutritional index in patients with bladder cancer: a systematic review and meta-analysis[J]. Front Oncol,2024,14:1486389.
[35] YANG Y, GAO P, CHEN X, et al. Prognostic significance of preoperative prognostic nutritional index in colorectal cancer: results from a retrospective cohort study and a meta-analysis[J]. Oncotarget,2016,7(36):58543-58552.

PDF(4076 KB)

Accesses

Citation

Detail

段落导航
相关文章

/